A six-month randomized trial and a long-running German population study found that a blood-fat pattern associated with regular peanut consumption was linked to an approximately 11% lower risk of developing Type 2 diabetes, with researchers estimating that body mass index may explain much of the association.

By yourNEWS Media Newsroom

Regular peanut consumption may produce measurable changes in circulating fats that are associated with a lower long-term risk of Type 2 diabetes, according to new research combining a controlled dietary experiment with data from a large European population study.

The research, published Sept. 17 in The American Journal of Clinical Nutrition, found that eating peanuts or peanut products altered dozens of lipid measurements in the blood. Researchers then identified a similar lipid pattern in participants from the long-running EPIC-Potsdam cohort and found that people with higher scores for that pattern had a modestly lower risk of subsequently developing Type 2 diabetes.

The study combined two different research designs rather than directly following peanut eaters until they developed diabetes. The first, a six-month randomized clinical trial known as ARISTOTLE, involved 63 healthy adults. The second used blood samples and health outcomes from the prospective EPIC-Potsdam study in Germany.

Researchers said the combined approach allowed them to first determine which blood lipids changed in response to peanut fat and then investigate whether that same metabolic pattern was associated with future disease.

The resulting “peanut lipidomic signature,” or PeLS, was associated with an 11% lower risk of Type 2 diabetes for every one-standard-deviation increase in the score. The hazard ratio was 0.89, with a 95% confidence interval of 0.80 to 0.99.

The pattern was not associated with a significant reduction in cardiovascular disease, an important distinction in interpreting the findings.

Six Months of Peanut Intake Altered 51 Blood-Fat Measurements

The ARISTOTLE trial enrolled healthy young adults between ages 18 and 33 and randomly assigned them to one of three daily interventions for six months.

Participants consumed either 25 grams of skin-roasted peanuts, 32 grams of peanut butter or 32 grams of a control butter made from peanut oil. Twenty-five grams of peanuts is roughly equivalent to a small handful, while 32 grams of peanut butter is approximately two tablespoons.

Researchers collected blood samples before and after the intervention and conducted detailed lipidomic analyses designed to measure changes across numerous classes of fats circulating in the bloodstream.

The intervention affected 51 fatty-acid measurements within different lipid classes, according to the published study results.

Most of the changes involved very long-chain saturated fatty acids, particularly fats incorporated into sphingolipids. These fatty acids contain chains of 20 or more carbon atoms and can behave metabolically differently from the shorter-chain saturated fats commonly associated with foods such as butter.

Peanuts have a distinctive fatty-acid profile that includes both substantial amounts of monounsaturated fat and very long-chain saturated fatty acids. Although commonly grouped nutritionally with nuts, peanuts are botanically legumes.

Researchers identified particularly consistent changes involving very long-chain fatty acids such as C24:0, also known as lignoceric acid. By combining the lipid measurements that responded to the intervention, researchers constructed a composite blood-fat signature associated with peanut fat intake.

Earlier work using participants in the same ARISTOTLE trial had also found increases in circulating very long-chain saturated fatty acids after six months of eating whole peanuts or peanut butter. That research also found differences in how those fats were absorbed depending on whether peanuts were consumed whole or as peanut butter.

The new study took that work further by asking whether the blood-fat pattern produced by peanut consumption was related to future diabetes risk.

Researchers Tested the Signature Against Long-Term Diabetes Outcomes

A six-month feeding trial cannot determine whether someone will develop Type 2 diabetes years or decades later. Researchers therefore turned to EPIC-Potsdam, a large prospective population study established in Germany in the 1990s.

The EPIC-Potsdam cohort enrolled 27,548 adults from Potsdam and surrounding communities. Participants were generally between 35 and 65 when recruited and underwent blood testing, physical measurements and detailed assessments of diet, health and lifestyle.

Researchers continued contacting participants every two to three years and investigated reported diagnoses of Type 2 diabetes.

For the new peanut analysis, researchers used a nested case-cohort design. The diabetes analysis included 774 people who developed Type 2 diabetes, along with participants from a randomly selected comparison group.

Scientists calculated a peanut lipidomic signature for participants using stored baseline plasma and compared the resulting scores with later physician-verified diabetes diagnoses.

Each one-standard-deviation increase in the peanut-related lipid score was associated with an approximately 11% lower risk of Type 2 diabetes.

Researchers adjusted their statistical models for a wide range of factors that could otherwise influence diabetes risk, including age, sex, calorie intake, smoking, alcohol consumption, education, physical activity, blood pressure, medication use and overall dietary patterns.

The association remained after those adjustments.

The findings do not mean that a particular concentration of peanut-derived fats guarantees protection against diabetes. The lipid score represented a statistical pattern across multiple circulating fats rather than a single protective molecule.

BMI Appeared to Explain Much of the Association

One of the study’s most notable findings emerged when researchers examined body mass index.

After BMI was introduced into the statistical model, much of the association between the peanut lipid signature and lower diabetes risk weakened. Researchers estimated that BMI could potentially explain about 89% of the relationship, with a wide 95% confidence interval ranging from 57% to 100%.

The researchers described that mediation analysis as hypothesis-generating rather than definitive evidence of a causal mechanism.

The result suggests that body composition may be an important link between peanut intake and diabetes risk rather than the altered fatty acids directly improving blood glucose on their own.

Waist and hip measurements produced a broadly similar pattern, according to the research. In contrast, blood glucose and inflammatory markers did not appear to explain the association to the same degree.

That finding is potentially significant because peanuts are calorie-dense. A small serving contains substantial fat and energy, which might appear inconsistent with weight control.

Previous clinical research, however, has often found that adding moderate amounts of peanuts or other nuts to a diet does not lead to the amount of weight gain that might be predicted solely from their calorie content.

Several possible explanations have been proposed. Whole nuts are highly satiating, which may prompt people to reduce calories from other foods. Their physical structure can also prevent complete absorption of some of their fat, particularly when they are eaten whole rather than finely processed.

The ARISTOTLE trial itself previously found differences in fat bioaccessibility between whole peanuts and peanut butter. Participants consuming whole peanuts excreted more very long-chain fatty acids in their stool than those eating peanut butter, suggesting the physical structure of the food affects how efficiently its fat is absorbed.

Researchers have also investigated whether peanut consumption changes energy expenditure or fat oxidation, although the new study does not establish those mechanisms as the reason for the observed diabetes association.

Not All Saturated Fat Appears to Behave the Same Way

The research also adds to evidence that describing all saturated fatty acids as biologically identical can obscure important metabolic differences.

The very long-chain saturated fatty acids found in peanuts include C20:0, C22:0 and C24:0. Observational studies have repeatedly investigated these circulating fats because they have sometimes been associated with lower cardiometabolic risk despite belonging chemically to the saturated-fat family.

A separate 2025 EPIC-Potsdam analysis of very long-chain saturated fatty acids found that their relationships with Type 2 diabetes and cardiovascular disease varied according to which lipid molecules contained them and how they interacted with other circulating fats.

That complexity means the new results should not be interpreted as evidence that saturated fat generally protects against diabetes. Food source, fatty-acid chain length, lipid class and the surrounding dietary pattern can all matter.

Peanuts also provide monounsaturated fats, protein, fiber, minerals and plant compounds, making it difficult to isolate one component as solely responsible for their possible metabolic effects.

The control product used in ARISTOTLE contained peanut oil but lacked the fiber and polyphenols present in whole peanuts and peanut butter, allowing researchers to examine changes associated specifically with peanut fat while also comparing different forms of peanut consumption.

Study Does Not Prove Peanuts Prevent Diabetes

Researchers emphasized several limitations.

The randomized portion of the research was small, involving only 63 participants, and those participants were young and healthy. People with obesity, diabetes and other chronic diseases were excluded from the original ARISTOTLE trial, meaning the biological response could differ among older adults or people who already have metabolic disease.

The long-term diabetes analysis was observational.

Researchers did not randomly assign thousands of people to eat peanuts for decades and then compare diabetes diagnoses. Instead, they identified a blood-fat pattern generated from the short-term experiment and examined whether people who naturally had more of that pattern in the German cohort developed diabetes less frequently.

That design can identify associations but cannot establish that eating peanuts caused the lower diabetes risk.

The researchers themselves described the BMI mediation analysis as exploratory. Although the statistical findings suggest body weight or composition could account for much of the association, they cannot establish precisely how peanuts, BMI and diabetes risk interact biologically.

The research also found no significant association between the peanut lipidomic signature and cardiovascular disease. The hazard ratio for cardiovascular disease was 1.01, indicating essentially no detectable difference in risk in the analysis.

Those limitations make the findings substantially more measured than a conclusion that eating peanuts prevents diabetes.

Instead, the research shows that regular peanut intake produces a recognizable change in circulating fats and that people displaying more of that lipid pattern had modestly lower rates of Type 2 diabetes in a separate long-term population study.

A Small Daily Serving Produced Measurable Changes

The amounts used in the clinical trial were readily achievable through an ordinary diet.

Participants ate 25 grams of skin-roasted peanuts or 32 grams of peanut butter each day — approximately a small handful of peanuts or two tablespoons of peanut butter.

After six months, those amounts were sufficient to generate measurable differences in circulating lipids.

For people who already consume peanuts, the findings suggest they can fit within a dietary pattern associated with metabolic health, particularly when replacing foods containing less favorable fat profiles rather than simply being added on top of an existing diet.

That substitution may be important.

In population data, the peanut-related lipid signature tracked positively with overall nut consumption and tended to move in the opposite direction from butter consumption, suggesting that dietary choices involving peanuts may partly reflect replacing other fat sources.

Plain or minimally processed peanuts and peanut butter without large amounts of added sugar may also differ nutritionally from candy-coated peanuts, heavily sweetened spreads or peanut-containing desserts.

Peanuts are not appropriate for people with peanut allergies, which can cause severe and potentially life-threatening reactions.

For everyone else, the new findings add another piece to a larger body of research examining nuts, legumes and cardiometabolic health. They do not establish peanuts as a diabetes treatment, but they provide evidence that modest daily consumption can alter the human lipidome in ways that correspond with lower Type 2 diabetes risk.

The strongest clue in the new analysis may ultimately be the role of body composition. Researchers found that the apparent diabetes advantage associated with the peanut lipid signature largely diminished after BMI was considered, suggesting that any long-term benefit may depend less on a single unusual fatty acid and more on how regular peanut consumption fits into weight regulation, food substitution and the overall diet.

Explainer Infographic

Source: Natural News
Original article